s and the increasing number of therapies being developed for this indication, Spectral is well-positioned to drive the adoption of the EAA(TM), which can be used to identify patients, enable therapeutics and monitor treatment. In March 2009, Spectral obtained the exclusive development and commercial rights in the U.S. for Toraymyxin(TM), a therapeutic for the treatment of sepsis that removes endotoxin from the bloodstream. Spectral will seek FDA approval for Toraymyxin(TM) and intends to commercialize the product together with EAA(TM). Spectral is listed on TSX under the symbol SDI.
Information in this news release that is not current or historical factual information may constitute forward-looking information within the meaning of securities laws. Implicit in this information, particularly in respect of the future outlook of Spectral and anticipated events or results, are assumptions based on beliefs of Spectral's senior management as well as information currently available to it. While these assumptions were considered reasonable by Spectral at the time of preparation, they may prove to be incorrect. Readers are cautioned that actual results are subject to a number of risks and uncertainties, including the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of Spectral to take advantage of business opportunities in the biomedical industry, the granting of necessary approvals by regulatory authorities as well as general economic, market and business conditions, and could differ materially from what is currently expected.
The TSX has not reviewed and does not accept responsibility for the
adequacy or accuracy of this statement.
Page: 1 2 Related biology technology :1
|SOURCE Spectral Diagnostics Inc.|
Copyright©2009 PR Newswire.
All rights reserved
. Spectral announces 2008 financial results2
. Spectral signs exclusive license agreement to bring sepsis therapeutic to the U.S. market3
. Surface plasmon resonances of metal nanoparticles in array can have narrower spectral widths4
. Spectral announces third quarter 2008 results5
. Spectral to bring anti-sepsis therapy to the U.S. market6
. Spectral announces exclusive distribution agreement in Russia for its EAA(TM) Sepsis Diagnostic Assay7
. Spectral announces continuing support for the combination of EAA(TM) and anti-endotoxin therapeutics8
. Spectral announces presentation of data on improving sepsis patient management with EAA(TM) and Toraymyxin(TM) combination9
. Spectral and Toray expand collaboration to include new geographic territories10
. Spectrals EAA(TM) to be used in Phase III study for a sepsis anti-endotoxin therapy11
. Spectral announces new findings on the effectiveness of EAA(TM)/Toraymyxin(TM) at the 28th International Symposium on Intensive Care and Emergency Medicine